UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR
SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number  001-38135    


DOVA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)


240 Leigh Farm Road, Suite 245
Durham, North Carolina 27707
(919) 748-5975
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)


Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)


None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)


Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 
Rule 12g-4(a)(1)
☒
 
 
Rule 12g-4(a)(2)
☐
 
 
Rule 12h-3(b)(1)(i)
☒
 
 
Rule 12h-3(b)(1)(ii)
☐
 
  Rule 15d-6
☐
 
 
Rule 15d-22(b)
☐  


Approximate number of holders of record as of the certification or notice date: One (1)

Pursuant to the requirements of the Securities Exchange Act of 1934, Dova Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.


  DOVA PHARMACEUTICALS, INC.  
       
Date: November 22, 2019
By:
/s/ Marc Banjak  
    Name: Marc Banjak  
    Title: General Counsel  
       



Dova Pharmaceuticals (NASDAQ:DOVA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Dova Pharmaceuticals.